小青龙汤对慢性阻塞性肺疾病患者气道炎症及临床转归的影响

Abstract
Figure/Table
References (25)
Related Citation (10)

Download: PDF (734 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To discuss the influence of Xiaoqinglong Decoction on airway inflammation and clinical outcome of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 118 cases of patients with AECOPD admitted to Panyu Hospital of Chinese Medicine in Guangzhou City from January 2017 to January 2018 were enrolled as objects and divided into different groups according to critical degrees of arterial blood gas. 60 AECOPD patients without respiratory failure were included in non-respiratory failure group and 58 AECOPD patients with type Ⅱ respiratory failure were included in respiratory failure group. They were in depth grouped by random number table method: 30 cases in non-respiratory failure observation group, 30 cases in non-respiratory failure control group; 30 cases in respiratory failure observation group, 28 cases in respiratory failure control group. All patients were given standard treatment of western medicine treatment; patients of observation groups were given Xiaoqinglong Decoction for 21 days on the basis of the treatment above. Procalcitonin (PCT), interleukin 6 (IL-6) and C-reaction protein (CRP) were detected before and after treatment and 90-day follow-up was done. Serum IL-6, body mass index, airflow obstruction, dyspnea, and exercise capacity index (BODE index) at 30th, 60th, 90th day were monitored. The acute attack frequency of COPD and death events were recorded. The indices above in the observation group and control group, two observation groups and four groups were compared respectively. Results The differences in serum IL-6 and BODE index before treatment among four groups were statistically significant, and the indices were higher and the disease condition was worse in the respiratory failure group (P ＜ 0.05). The differences in serum PCT, CRP, IL-6 and BODE index between non-respiratory failure observation group and non-respiratory failure control group before treatment (first day) were not statistically significant (P ＞ 0.05). The serum CRP at 7th day and IL-6 at 90th day of non-respiratory failure observation group were decreased more obviously than those of control group, the differences were statistically significant (P ＜ 0.05). The BODE index at 90th day of non-respiratory failure observation group was improved more obviously compared with that of control group (P ＜ 0.05). The differences in serum PCT, CRP, IL-6 and BODE index between respiratory failure observation group and respiratory failure control group before treatment were not statistically significant (P ＞ 0.05). The serum PCT and CRP at 7th day of respiratory failure observation group was decreased more obviously compared with that of control group, there was statistically significant difference (P ＜ 0.05); the serum IL-6 at 30th day and 90th day were decreased more remarkably compared with those of control group, the differences were statistically significant (P ＜ 0.05). The BODE index of respiratory failure observation group at 30th, 60th, 90th day improved more obviously compared with those of control group, the differences were statistically significant (P ＜ 0.05). The number of patients that suffered from acute exacerbation of COPD in respiratory failure observation group in 90 follow-up days was less than that of control group (P ＜ 0.05). The differences in serum PCT and CRP between two observation groups before treatment were not statistically significant (P ＞ 0.05), and the difference in serum PCT at 7th day of treatment was not statistically significant (P ＞ 0.05). The difference in patients that suffered from acute exacerbation of COPD between two observation groups in 90 follow-up days was not statistically significant (P ＞ 0.05). Conclusion Xiaoqinglong Decoction can improve airway inflammation of AECOPD patients, reduce acute exacerbation frequency of AECOPD with type Ⅱ respiratory failure, and improve survival quality and clinical prognosis of AECOPD patients.

Key words： Xiaoqinglong Decoction Acute exacerbation of chronic obstructive pulmonary disease Inflammatory factor BODE index Acute exacerbation frequency

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LEI Peishan SU Xiaoyin WANG Qiang WU Zhijian

Cite this article:

LEI Peishan SU Xiaoyin WANG Qiang WU Zhijian. Influence of Xiaoqinglong Decoction on airway inflammation and clinical outcome of patients with chronic obstructive pulmonary disease[J]. 中国医药导报, 2018, 15(18): 131-135,139.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I18/131

[1] 黄斐斐，张雯，陈莲，等.肺康复在慢性阻塞性肺疾病急性加重患者中的应用进展[J].中国全科医学，2017，20（18）：2176-2182.
[2] 景璇，郭洁，赵小静，等.慢性阻塞性肺疾病急性加重期中医治疗研究进展[J].世界中医药，2016，11（7）：1384-1388.
[3] 赖乾，张毅，段小红，等.中医非药物治疗慢性阻塞性肺疾病稳定期的临床研究进展[J].中国中医药信息杂志，2018，25（2）：133-136.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中华结核和呼吸杂志，2013，36（4）：255-264.
[5] 李建生，李素云，余学庆.慢性阻塞性肺疾病中医诊疗指南（2011版）[J].中医杂志，2012，53（1）：80-84.
[6] 慢性阻塞性肺疾病急性加重（AECOPD）诊治专家组.慢性阻塞性肺疾病急性加重（AECOPD）诊治中国专家共识（2017年更新版）[J].国际呼吸杂志，2017，37（14）：1041.
[7] 赵莹，孔灵菲.诱导痰检测技术及其临床应用[J].中国实用内科杂志，2007，27（13）：1070-1071.
[8] 张晓瑜，闫蕊.巨噬细胞刺激蛋白在慢性阻塞性肺疾病发病机制中的作用研究[J]临床医学研究与实践，2018， 3（2）：88-89.
[9] 郑永艳，周园，周联.小青龙汤抗过敏作用及其机制研究[J].时珍国医国药，2017，28（5）：1052-1055.
[10] 庄雅娟，李超云，贯丽娟，等.替加环素联合小青龙汤雾化治疗耐药鲍曼不动杆菌致呼吸机相关性肺炎疗效及对血清炎性因子的影响[J].现代中西医结合杂志，2018， 27（5）：492-494.
[11] 党斌温.对慢性阻塞性肺疾病防治全球倡议2017更新的几点看法[J].中华结核和呼吸杂志，2017，40（5）：386-388.
[12] 宋淑范，辛平.炎症细胞因子IL-1β，IL-6，TNF-α，IL-8对慢性阻塞性肺疾病模型小鼠肺癌生长及转移的影响[J].临床与病理杂志，2017，37（11）：2323-2331.
[13] 刘娟，王军，邓庆华，等.慢性阻塞性肺病炎症机制与中药单体成分对其治疗作用的研究进展[J].中国药房，2018，29（8）：1145-1148.
[14] 许文飞，鞠远荣.呼出一氧化氮在慢性阻塞性肺疾病管理中的研究进展[J].中国医刊，2016，51（5）：21-24.
[15] 朱敏峰.血清c-反应蛋白、白介素-6及白介素-10水平与慢性阻塞性肺疾病的相关性研究[D].苏州：苏州大学，2014.
[16] 胡晓飞，汪晔，俞计明.稳定期COPD患者全身炎症水平与GOLD分级及BODE指数关系的研究[J].中国现代医生，2017，55（28）：12-15.
[17] 马秉.降钙素原及D-二聚体对慢性阻塞性肺疾病的预后分析[J].齐齐哈尔医学院学报，2017，38（3）：304-305.
[18] 刘志刚.慢性阻塞性肺疾病治疗中炎性反应因子、降钙素原、BODE指数及机械通气的相关性研究[J].吉林医学，2017，38（6）：1026-1028.
[19] 雷佩珊，赖静文.PCT在有基础疾病的老年AECOPD患者中的表达[J].中国热带医学，2015，15（4）：469-472.
[20] 王慎临，杨朝，张丽萍.维生素D与COPD患者下呼吸道细菌定植及痰相关炎症因子关系的研究[J].宁夏医药杂志，2017，39（11）：964-967.
[21] 释涤凡.益气养阴、化痰活血法治疗慢性阻塞性肺疾病稳定期76例临床疗效观察[J].中国现代医生，2017，55（29）：122-125.
[22] 田雨.细菌感染在COPD患者病情进展中的变化特点[J].临床合理用药杂志，2016，9（1A）：20-22.
[23] 梁权，樊启财，陈双杰.下呼吸道细菌定植对稳定期COPD患者免疫细胞和炎症因子水平的影响分析[J].内科，2017，12（2）：214-232.
[24] 任玉娇，张伟.清热化痰合活血利水法治疗慢性阻塞性肺疾病急性加重期探讨[J].西部中医药，2017，30（9）：96-98.
[25] 徐瑜，罗百灵.慢性阻塞性肺疾病急性加重期患者血hs-CRP、CA-125和IL-6水平变化及临床意义[J].临床肺科杂志，2017，22（3）：458-460.